Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
38.5M
-
Number of holders
-
31
-
Total 13F shares, excl. options
-
5.12M
-
Shares change
-
-18.6K
-
Total reported value, excl. options
-
$8.55M
-
Value change
-
-$31.8K
-
Number of buys
-
7
-
Number of sells
-
-10
-
Price
-
$1.67
Significant Holders of Protara Therapeutics, Inc. - Common Stock (TARA) as of Q3 2023
33 filings reported holding TARA - Protara Therapeutics, Inc. - Common Stock as of Q3 2023.
Protara Therapeutics, Inc. - Common Stock (TARA) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.12M shares
of 38.5M outstanding shares and own 13.3% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2.69M shares), ORBIMED ADVISORS LLC (773K shares), VANGUARD GROUP INC (428K shares), Boxer Capital, LLC (209K shares), BAKER BROS. ADVISORS LP (200K shares), Ikarian Capital, LLC (189K shares), Privium Fund Management (UK) Ltd (120K shares), GEODE CAPITAL MANAGEMENT, LLC (78.5K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (64K shares), and RENAISSANCE TECHNOLOGIES LLC (60.1K shares).
This table shows the top 31 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.